Sino Biopharmaceutical Ltd

01177

Company Profile

  • Business description

    Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

  • Contact

    1 Harbour Road
    Unit 09, 41st Floor, Office Tower, Room 4109
    Convention Plaza
    Wanchai
    Hong Kong
    HKG

    T: +852 28029886

    https://www.sinobiopharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    23,056

Stocks News & Analysis

stocks

Fair value downgraded for ASX heavyweight

Our capital allocation rating was also lowered due to balance sheet weakness.
stocks

ChatGPT enters the retail space and one company surges

Investors cheer the ability to purchase directly from ChatGPT.
stocks

Alibaba fair value increases by 49%

Stronger-than-expected AI demand internationally and domestically.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,136.6015.100.17%
CAC 407,930.2234.280.43%
DAX 4023,967.6086.880.36%
Dow JONES (US)46,397.8981.820.18%
FTSE 1009,411.4461.010.65%
HKSE26,855.56232.680.87%
NASDAQ22,660.0168.860.30%
Nikkei 22544,550.85381.78-0.85%
NZX 50 Index13,433.99141.631.07%
S&P 5006,688.460.000.00%
S&P/ASX 2008,845.7012.300.14%
SSE Composite Index3,882.7820.250.52%

Market Movers